Dopamine (DA) is a major neurotransmitter in the central nervous system (CNS) that plays important roles in behaviour and cognition, ranging from movement to emotion, sensitization to addiction, and development to plasticity. All DA receptors belong to a superfamily of large peptides that are coupled to G-proteins and modified by attached carbohydrate, lipid-ester or phosphate groups. They are characterized by having seven hydrophobic transmembrane-spanning regions, as well as a functionally critical third intracytoplasmic loop that interacts with G-proteins and other effector molecules to mediate the physiological and neurochemical effects of the receptors. Based on their pharmacological profiles, including their effects on different signal transduction cascades, these receptors are currently divided into two families: the D 
Dopamine (DA) is a major neurotransmitter in the central nervous system (CNS) that plays important roles in behaviour and cognition, ranging from movement to emotion, sensitization to addiction, and development to plasticity. All DA receptors belong to a superfamily of large peptides that are coupled to G-proteins and modified by attached carbohydrate, lipid-ester or phosphate groups. They are characterized by having seven hydrophobic transmembrane-spanning regions, as well as a functionally critical third intracytoplasmic loop that interacts with G-proteins and other effector molecules to mediate the physiological and neurochemical effects of the receptors. Based on their pharmacological profiles, including their effects on different signal transduction cascades, these receptors are currently divided into two families: the D 1 suggested to be a potential target in the treatment of neurological disorders such as schizophrenia, and drug abuse. 5 In schizophrenia, a blockade of D 2 receptors has been considered to be the main mechanism responsible for the efficacy of antipsychotics, 6 but the complex profiles of some atypical drugs challenged this assumption, that is, clozapine exhibits activity at multiple receptors. 7 Now there is an increasing body of clinical evidence that supports the notion that multi-target ligands may be more efficacious than strictly selective agents in the treatment of schizophrenia and other CNS disorders. 8 Among multiple receptor subtypes, D 3 receptors have been proposed as putative targets for atypical antipsychotic drugs, and thus, some works suggest that D 3 antagonism may cause cognitive enhancement 9 and a lack of catalepsy.
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In an attempt to prove these hypotheses, an intensive effort has been directed toward the development of selective ligands for dopamine D 3 receptors.
11 Some of these D 3 ligands are now in ongoing clinical development as potential therapeutics for the aforementioned disorders. The compound BP 897 ( Fig. 1) , which was initially identified as a partial agonist but later displayed an antagonist property in other experiments, could reduce cocaineseeking behaviour in rats. 12 The superpotent benzothiophene der- In an attempt to design a novel class of D 3 ligands to study this receptor system, we report herein the synthesis and binding affinity of a new series of potential D 3 receptor ligands (Fig. 2) . This novel series is based on the benzolactam scaffold and maintains three characteristic elements of many dopamine D 3 receptor antagonists: (1) an amine moiety, (2) a spacer, usually a linear alkyl chain, and (3) a hydrophobic residue, often connected through an amide bond. 15 The size of the lactam cycle varied from a six to eightmembered ring, the length of the alkyl spacer, from propyl to pentyl, and the aryl substituent of the piperazine ring was varied to achieve a set of compounds that allows us to evaluate some of the structural requirements for high binding affinity and selectivity on the D 3 receptor. The synthetic route for the preparation of the target arylpiperazinylalkylbenzolactams started from a commercially available benzocycloalkanone (indanone, tetralone or benzosuberone), with the aim of achieving the corresponding benzolactam by a Schmidt rearrangement (Scheme 1). The Schmidt reaction, according to the literature, gives benzolactam 3 as the major product; however, by changing the reaction medium from trichloroacetic acid, 16 polyphosphoric acid 17 or sulfuric acid 18 to concentrated hydrochloric acid, 19 the desired benzolactams 2 can be obtained in moderate yields (42%). This reaction was optimized by adding two equivalents of the sodium azide, 20 and it resulted in a 75-85% yield of the benzolactam type 2. Nevertheless, this technique was not useful in case the of the benzosuberone, where the benzolactam 2c was obtained in only a 7% yield, whereas 3c was obtained in an 87% yield. Depending on the length of the spacer, one of two synthetic routes was used starting from the benzolactams 2a-c, as shown in Scheme 2. In the case of a propyl spacer (method A), chlorides 4a-f were prepared from commercially available piperazines by alkylation with 1-bromo-3-chloropropane in acetone using 25% aqueous NaOH as a base. The corresponding N-(3-chloropropyl)piperazines 4a-f were obtained with 60-80% yields. Alkylation of the benzolactams 2a-c was achieved when they were treated with the different chloropropylpiperazines 4a-f in anhydrous benzene after deprotonation with NaH, resulting in the final compounds 5a-f, 6a-f and 7b in a 60-85% yield.
Alkylation of piperazines with 1-bromo-4-chlorobutane or 1-bromo-5-chloropentane, following method A (Scheme 2), produced an azaspiroazonium salt. Although the reaction of this salt with imides has been described in the literature, 21 in our case the desired products were obtained in very low yields. Consequently, method B (Scheme 2) was applied for the synthesis of N-arylpiperazinylbutyl-and pentyl-benzolactams. Alkylation of the benzolactams 2a,b with 1-bromo-4-chlorobutane or 1-bromo-5-chloropentane in anhydrous benzene using sodium hydride as a base gave the corresponding amides 8-10 in acceptable yields, depending on the size of the benzolactam ring. Higher yields were obtained with the six-membered benzolactams 8 22 (62%) and 10 (75%), and lower yields with the seven-membered benzolactam 9 22 (50%). For alkylation of piperazines, the best results were obtained by reacting the arylpiperazine and chloroalkylbenzolactam with potassium carbonate as a base and potassium iodide as a catalyst in methylisobutylketone. The alkylated benzolactams 11a-h, 12a-f and 13a were obtained in a 30-75% yield.
The affinity of the new compounds for cloned human D 1 , D 2 and D 3 receptors was evaluated in in vitro binding assays using Table 1 .
With the aim of rationalizing the observed experimental results, structural models of the complexes between some of the most representative compounds of this series and the D 2 and D 3 receptors were obtained. It must be stressed that such models were built using computational methods and therefore do not have the value of an experimental result (e.g., a crystallographic structure). Even so, the inspection of such structures allows us to formulate an interesting hypothesis about the physicochemical justifications for the observed pharmacological results. A full description of the methods used for the building of such models is provided as Supplementary data and can also be found in Selent et al. 25 For the description of these models here, the residues in the transmembrane domains (TM) will be named using the Ballesteros and Weinstein indexing system.
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One of the points studied here is the length of the linker between the lactam and the piperazine ring. Available data indicate that the length of this bridge decisively influences the affinity of these compounds to the D 2 and D 3 receptors, whereas on the D 1 receptor the length of the bridge seems to have little influence. Lengthening the bridge from propyl to butyl resulted in a beneficial effect on the affinity at the D 2 and D 3 receptors. Propyl derivatives such as 5a or 6a, with modest D 2 and D 3 affinities became high affinity ligands when transformed into their butyl analogues 11a The analysis of the structural models obtained for the complexes between ligands of the propyl and butyl series and the D 2 and D 3 receptors suggests an explanation for the experimental results observed. In all of the structures obtained, the same key interactions were observed: besides the well-known salt bridge (D3.32), which is essential for ligand binding, the aryl ring is fixed in a hydrophobic sandwich consisting of V3.33 and F6.52 and the polar aryl substituents interact with the Ser residues in TM5. The benzolactam ring is directed towards the TM 2, 1, 7 regions and is laterally stabilized by a hydrophobic interaction with L2.64 and Y7.35 in both sides of the pocket. In the ligands with a butyl linker (like 11a in Fig. 3, in grey) , the benzolactam ring can establish a H-bond between the carbonyl oxygen of the benzolactam and the side chain of H-bond donor residues in TM7 (T7.39 in D 2 and S7.36 in D 3 ). On the other hand, the compounds with a propyl linker (like 5a in Fig. 3 , in green) orient the benzolactam carbonyl oxygen in a different position from which it is not possible to establish an equivalent H-bond neither in the D 2 nor in the D 3 receptor. As a consequence of this lack of polar anchorage, the docking simulation results suggest alternate poses for some propyl compounds, in which the lactam moiety is directed either upwards or downwards and out of the common binding pocket.
Another aim of this work was to study the influence of the lactam ring size on the affinity of the dopamine receptors and the selectivity of these compounds. On D 3 receptors, increasing the size of the lactam ring from 6 to 7 members produced, in all cases of available data (except 11c ? 12c), a slightly positive effect on affinity. In addition, the series 5b ? 6b ? 7b seems to indicate that the optimum size of the lactam ring for affinity to the D 3 receptors would be 7 members. On D 2 receptors, the effect is similar to the previous case: increasing the size of the lactam ring from 6 to 7 produces an advantageous effect on affinity. One exception is the compound 11f, where the expansion of its lactam ring from 6 to 7 members resulted in a drop in the affinity. As for the effect on the D 1 receptors, we can say that, in most cases, there was no significant change in the affinity. As regards the selectivity, the compounds bearing a six-membered lactam were generally more D 3 selective than derivatives with a lactam of seven members. The exception was found in the derivative 12b, which has a relatively high affinity for D 3 (K i = 40 nM, pK i = 7.39) while lacking an affinity for D 1 or D 2 receptors.
An observation of the structural models obtained for the complexes suggested that the minor positive effect of the lactam ring size (six-or seven-membered ring) on the D 2 and D 3 receptor affinity could be explained by the slightly more favourable contacts of the seven-membered lactam ring compounds with the nearby hydrophobic residues than the equivalent six-membered ring compounds. This is illustrated in Figure 4 , the structure of 11a (grey) and 12a (green) in complex with D 2 . The aliphatic carbons of the seven-membered ring are located closer to the V2.61, L2.64 and the I1.83, located in the extracellular loop 2 (the residue of the binding site not conserved between the D 2 and D 3 receptors). Interestingly, the effect on the antagonist affinity of V2.61F 27 and L2.64S 27 mutations in the D 2 receptor supports our finding. Furthermore, mutational studies of the I1.83 indicate that, due to the observed impact on the ligand binding, this residue should be close to the core of the binding pocket. 28 In looking at the influence of the phenylpiperazine moiety, we have analysed eight N-substituted piperazines with aryl or heteroaryl groups: 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-pyridyl, 2-pyrimidyl, 3-trifluoromethylphenyl, 2-chlorophenyl, and 2,3-dichlorophenyl. The aryl groups that produced a greater affinity for the D 3 receptor were the 2-methoxyphenyl, 2-chlorophenyl and 2,3-dichlorophenyl. Moreover, the substituents of the piperazine ring that led to a greater selectivity of the D 3 over D 2 were 2-pymimidyl, and especially 4-methoxyphenyl. In the compounds bearing a methoxyphenylpiperazine, the position of the methoxy group in the aromatic group critically influences the selectivity and affinity for dopamine receptors. For example, on the D 2 receptor, the pK i values of the 2-methoxyphenylpiperazines 11a and 12a were 7.91 and 8.44, respectively, while its position isomers, the 4-methoxyphenylpiperazines 11b and 12b, showed no affinity for this receptor. The same can be said for the isomers 6a (pK i = 6.10) and 6b (pK i < 4), which carry a propyl bridge. Displacement of the methoxy group in the aromatic ring from position 2 to 4 produced, in all cases, a decrease in the affinity for the three receptors, though selectivity of the D 3 receptors increased significantly. This indicates that the change of the location of the methoxy group is far more detrimental for D 1 (Table 2) . Compound 12f showed the highest affinity for the 5-HT 2A receptors (pK i = 7.98, K i = 10 nM), followed by 11g and the 2-methoxyphenyl derivatives 11a and 12a. Although the set of compounds is small and limits the conclusions we may draw, it can be said that the presence of chlorine atoms in the aromatic ring and a larger size of the lactam favour the affinity at this receptor. It is noteworthy that those compounds with higher affinities for D 2 and D 3 receptors (11a and 12a) have the smallest affinities for the 5-HT 2A receptor, and vice versa. As far as their potential as antipsychotics, the 5-HT 2A affinity, even though not high, may help to reduce the occurrence of extrapyramidal side effects, especially for the compound 12f. This compound is also the only one that shows greater affinity for 5-HT 2A than for the D 2 receptors (K i ratio 5-HT 2A /D 2 = 3.4), a profile that has been related to a potential behaviour as atypical antipsychotic.
33 A multi-target binding profile of these compounds and in vivo pharmacological assays to determine their antipsychotic activity and potential side effects are in progress, and will be reported in due course. In summary, we have synthesized a series of 26 new compounds with two fragments, a benzolactam and an arylpiperazine, linked by a propyl or butyl chain, and determined their affinities at the D 1 , D 2 , and D 3 receptors. Some of these compounds, for example 11a and 12a, showed a high D 2 and D 3 affinity and good selectivity over the D 1 receptor. Moreover, 12b displayed a D 3 affinity in the nanomolar range and a high selectivity over D 1 and D 2 . The SAR study on these compounds revealed that both the length of the bridge between the benzolactam and the piperazine and the size of the lactam ring decisively influenced their D 2 and D 3 affinities. Selected compounds showed moderate 5-HT 2A binding affinity, which could help to reduce the occurrence of extrapyramidal side effects should the compounds be used as antipsychotics. These data significantly improve our understanding of the D 3 pharmacophore and are expected to lead to novel approaches for the treatment of schizophrenia. Further optimization of this series will be reported in due course. 
